Hematopoietic growth factors: ESMO recommendations for the applications.
Greil
R
R
Third Medical Department of Hematology, Oncology, Hemostaseology, Infectious Diseases and Rheumatology, Paracelsus University Hospital, Salzburg, Austria.
Psenak
O
O
Roila
F
F
D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use; D016298:Hematopoietic Cell Growth Factors / Q000627:therapeutic use*; D019650:Hematopoietic Stem Cell Mobilization; D006801:Humans; D015994:Incidence; D009503:Neutropenia / Q000453:epidemiology / Q000517:prevention & control; D011092:Polyethylene Glycols; D011832:Radiation Injuries / Q000188:drug therapy; D011994:Recombinant Proteins
D016298:Hematopoietic Cell Growth Factors; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; C455861:pegfilgrastim; D011092:Polyethylene Glycols; D000069585:Filgrastim